INSM — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• We plan to continue to develop, acquire, in-license, or co-promote other first- and best-in-class commercial products, product candidates, and technologies, including those that address serious diseases that currently have significant unmet needs. We are focused broadly on serious disease therapeuti…

• Prior to 2019, we had not generated significant revenue and, through June 30, 2026, we had an accumulated deficit of $5.8 billion. We have financed our operations primarily through the public offerings of our equity securities, debt financings and revenue interest financings. Although it is difficul…

• Our ability to reduce our operating loss and begin to generate positive cash flow from operations depends on the continued success in commercializing our marketed products and obtaining full approval of ARIKAYCE in the US. Our continued success also depends on bringing additional clinical stage prod…

• The information below summarizes our recent updates and anticipated near-term milestones for our marketed products and our product candidates.

• •We continue to anticipate a regulatory decision for brensocatib for the treatment of NCFB in Japan in the second half of 2026.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• Prior to 2019, we had not generated significant revenue and, through March 31, 2026, we had an accumulated deficit of $5.8 billion. We have financed our operations primarily through the public offerings of our equity securities, debt financings and revenue interest financings. Although it is difficu…

• Our ability to reduce our operating loss and begin to generate positive cash flow from operations depends on the continued success in commercializing our marketed products and obtaining full approval of ARIKAYCE in the US. Our continued success also depends on bringing additional clinical stage prod…

• approval or, if any such approval is received, whether we will be able to successfully commercialize such products and whether or when we may become profitable.

• The information below summarizes our updates and anticipated near-term milestones for our marketed products and our product candidates.

• •In August 2025, BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for NCFB in adults and children 12 years and older, was approved in the US by the FDA. We launched BRINSUPRI in the US in the third quarter of 2025.